CH characteristics in various clinical contexts and selective pressures
| Selective pressure . | Clinical context . | CH characteristics . | Frequency (%) . |
|---|---|---|---|
| Extrinsic/intrinsic | Aging | DNMT3A | 8 |
| TET2 | 2 | ||
| ASXL1 | 2 | ||
| Extrinsic | AA | DNMT3A | 9 |
| ASXL1 | 13 | ||
| BCOR | 6 | ||
| PNH | TET2 | 8 | |
| SUZ12 | 3 | ||
| U2AF1 | 3 | ||
| ASXL1 | 3 | ||
| JAK2 | 5 | ||
| Chemotherapy | TP53 | 3 | |
| PPM1D | 15 | ||
| Intrinsic | DC | Backmutation | 11 |
| TERT promoter | 5 | ||
| FA | Gene conversion | 9 | |
| FANC point mutation | Case reports | ||
| FANC frameshift mutation | Case reports | ||
| SDS | Isochromosome 7q | 44 | |
| Monosomy 7 | 13 | ||
| Deletion 20q | 22 | ||
| TP53 | 48 | ||
| SCN | CSF3R | 12 | |
| MIRAGE syndrome | Deletion 7q | 18 | |
| UPD7q | 20 |
| Selective pressure . | Clinical context . | CH characteristics . | Frequency (%) . |
|---|---|---|---|
| Extrinsic/intrinsic | Aging | DNMT3A | 8 |
| TET2 | 2 | ||
| ASXL1 | 2 | ||
| Extrinsic | AA | DNMT3A | 9 |
| ASXL1 | 13 | ||
| BCOR | 6 | ||
| PNH | TET2 | 8 | |
| SUZ12 | 3 | ||
| U2AF1 | 3 | ||
| ASXL1 | 3 | ||
| JAK2 | 5 | ||
| Chemotherapy | TP53 | 3 | |
| PPM1D | 15 | ||
| Intrinsic | DC | Backmutation | 11 |
| TERT promoter | 5 | ||
| FA | Gene conversion | 9 | |
| FANC point mutation | Case reports | ||
| FANC frameshift mutation | Case reports | ||
| SDS | Isochromosome 7q | 44 | |
| Monosomy 7 | 13 | ||
| Deletion 20q | 22 | ||
| TP53 | 48 | ||
| SCN | CSF3R | 12 | |
| MIRAGE syndrome | Deletion 7q | 18 | |
| UPD7q | 20 |
DC, dyskeratosis congenita; SCN, severe congenital neutropenia.